Abstract
Rectal chlamydia is a common sexually transmissible infection (STI) in men who have sex with men (MSM) that is predominantly asymptomatic. The recommended treatment of azithromycin 1 g as a single oral dose has not been subject to randomized trials and so its efficacy is unknown. We conducted a retrospective case-note review of all MSM diagnosed at the Sydney Sexual Health Centre with asymptomatic rectal chlamydia in 2009. We identified 116 MSM who received azithromycin; 85 (73%) attended for the recommended re-test at varying times (median 78 days, range 21-372 days). Of the men who returned, 11 (13%) had a persistently positive result; we reviewed behavioural data to classify these men as probable re-infections (6/11) or possible treatment failures (5/11), suggesting an efficacy of 94%. Until a randomized controlled trial (RCT) is conducted, patients with rectal chlamydia should be encouraged to attend for a re-test at 6-12 weeks.
Original language | English |
---|---|
Pages (from-to) | 478-480 |
Number of pages | 3 |
Journal | International Journal of STD and AIDS |
Volume | 22 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2011 |
Externally published | Yes |
Keywords
- Antibiotic
- Azithromycin
- Chlamydia trachomatis
- High-risk behaviour
- MSM
- Treatment